Multiple Myeloma Coverage from Every Angle

Julie Côté, MD, on Clinical Implications of New Real-World Data on ASCT in Multiple Myeloma

Posted: Sunday, December 11, 2022

Julie Côté, MD, of CHU de Québec–Université Laval, discusses findings from a large study involving data from the Canadian Myeloma Research Group database involving the use of bortezomib and lenalidomide during the autologous stem cell transplant (ASCT) sequence. In patients with newly diagnosed disease, this regimen produced a median overall survival rate ≥10 years in most patients. The findings highlight the contribution of post-ASCT maintenance, particularly lenalidomide given until disease progression. But high-risk patients require additional strategies to optimize results, and further analyses to assess the relationship of patient characteristics, specific treatment details, and outcomes are in progress.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.